IL-13 and its genetic variants

effect on current asthma treatments.

Robert G. Townley, Muna Sapkota, Kiran Sapkota

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Airway hyperresponsiveness is an essential part of the definition of asthma associated temporally with exposure to allergens, certain respiratory viruses, pollutants such as ozone, and certain organic chemicals. Interleukin-13 (IL-13) is implicated as a central regulator in immunoglobulin E (IgE) synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. The importance of IL-13 in allergic disorders in humans is supported by consistent associations between tissue IL-13 levels and genetic variants in the IL-13 gene and asthma and related traits. Single-nucleotide polymorphisms in IL-13 are associated with allergic phenotypes in several ethnically diverse populations. Glucocorticoids are anti-inflammatory medications often used as maintenance therapy in acute and chronic asthma; however, some patients with severe asthma are steroid resistant. IL-13 remains elevated in glucocorticoid insensitive asthma but not in glucocorticoid sensitive asthma. Thus targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. This review focuses on the role of IL-13 on airway hyperresponsiveness and corticosteroids resistant asthma both preclinically and clinically.

Original languageEnglish
Pages (from-to)513-523
Number of pages11
JournalDiscovery medicine
Volume12
Issue number67
StatePublished - Dec 2011

Fingerprint

Interleukin-13
Asthma
Glucocorticoids
Therapeutics
Organic Chemicals
Ozone
Mucus
Allergens
Immunoglobulin E
Single Nucleotide Polymorphism
Adrenal Cortex Hormones
Hypersensitivity
Fibrosis
Anti-Inflammatory Agents
Steroids
Viruses
Phenotype

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Townley, R. G., Sapkota, M., & Sapkota, K. (2011). IL-13 and its genetic variants: effect on current asthma treatments. Discovery medicine, 12(67), 513-523.

IL-13 and its genetic variants : effect on current asthma treatments. / Townley, Robert G.; Sapkota, Muna; Sapkota, Kiran.

In: Discovery medicine, Vol. 12, No. 67, 12.2011, p. 513-523.

Research output: Contribution to journalReview article

Townley, RG, Sapkota, M & Sapkota, K 2011, 'IL-13 and its genetic variants: effect on current asthma treatments.', Discovery medicine, vol. 12, no. 67, pp. 513-523.
Townley RG, Sapkota M, Sapkota K. IL-13 and its genetic variants: effect on current asthma treatments. Discovery medicine. 2011 Dec;12(67):513-523.
Townley, Robert G. ; Sapkota, Muna ; Sapkota, Kiran. / IL-13 and its genetic variants : effect on current asthma treatments. In: Discovery medicine. 2011 ; Vol. 12, No. 67. pp. 513-523.
@article{af322ecff2fc4f8199319ee643945251,
title = "IL-13 and its genetic variants: effect on current asthma treatments.",
abstract = "Airway hyperresponsiveness is an essential part of the definition of asthma associated temporally with exposure to allergens, certain respiratory viruses, pollutants such as ozone, and certain organic chemicals. Interleukin-13 (IL-13) is implicated as a central regulator in immunoglobulin E (IgE) synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. The importance of IL-13 in allergic disorders in humans is supported by consistent associations between tissue IL-13 levels and genetic variants in the IL-13 gene and asthma and related traits. Single-nucleotide polymorphisms in IL-13 are associated with allergic phenotypes in several ethnically diverse populations. Glucocorticoids are anti-inflammatory medications often used as maintenance therapy in acute and chronic asthma; however, some patients with severe asthma are steroid resistant. IL-13 remains elevated in glucocorticoid insensitive asthma but not in glucocorticoid sensitive asthma. Thus targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. This review focuses on the role of IL-13 on airway hyperresponsiveness and corticosteroids resistant asthma both preclinically and clinically.",
author = "Townley, {Robert G.} and Muna Sapkota and Kiran Sapkota",
year = "2011",
month = "12",
language = "English",
volume = "12",
pages = "513--523",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "67",

}

TY - JOUR

T1 - IL-13 and its genetic variants

T2 - effect on current asthma treatments.

AU - Townley, Robert G.

AU - Sapkota, Muna

AU - Sapkota, Kiran

PY - 2011/12

Y1 - 2011/12

N2 - Airway hyperresponsiveness is an essential part of the definition of asthma associated temporally with exposure to allergens, certain respiratory viruses, pollutants such as ozone, and certain organic chemicals. Interleukin-13 (IL-13) is implicated as a central regulator in immunoglobulin E (IgE) synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. The importance of IL-13 in allergic disorders in humans is supported by consistent associations between tissue IL-13 levels and genetic variants in the IL-13 gene and asthma and related traits. Single-nucleotide polymorphisms in IL-13 are associated with allergic phenotypes in several ethnically diverse populations. Glucocorticoids are anti-inflammatory medications often used as maintenance therapy in acute and chronic asthma; however, some patients with severe asthma are steroid resistant. IL-13 remains elevated in glucocorticoid insensitive asthma but not in glucocorticoid sensitive asthma. Thus targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. This review focuses on the role of IL-13 on airway hyperresponsiveness and corticosteroids resistant asthma both preclinically and clinically.

AB - Airway hyperresponsiveness is an essential part of the definition of asthma associated temporally with exposure to allergens, certain respiratory viruses, pollutants such as ozone, and certain organic chemicals. Interleukin-13 (IL-13) is implicated as a central regulator in immunoglobulin E (IgE) synthesis, mucus hypersecretion, airway hyperresponsiveness, and fibrosis. The importance of IL-13 in allergic disorders in humans is supported by consistent associations between tissue IL-13 levels and genetic variants in the IL-13 gene and asthma and related traits. Single-nucleotide polymorphisms in IL-13 are associated with allergic phenotypes in several ethnically diverse populations. Glucocorticoids are anti-inflammatory medications often used as maintenance therapy in acute and chronic asthma; however, some patients with severe asthma are steroid resistant. IL-13 remains elevated in glucocorticoid insensitive asthma but not in glucocorticoid sensitive asthma. Thus targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. This review focuses on the role of IL-13 on airway hyperresponsiveness and corticosteroids resistant asthma both preclinically and clinically.

UR - http://www.scopus.com/inward/record.url?scp=84865811792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865811792&partnerID=8YFLogxK

M3 - Review article

VL - 12

SP - 513

EP - 523

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 67

ER -